tiprankstipranks
Trending News
More News >
Telix Pharmaceuticals Ltd. (AU:TLX)
ASX:TLX
Advertisement

Telix Pharmaceuticals (TLX) AI Stock Analysis

Compare
399 Followers

Top Page

AU:TLX

Telix Pharmaceuticals

(Sydney:TLX)

Rating:65Neutral
Price Target:
AU$19.50
▲(5.98% Upside)
Telix Pharmaceuticals Ltd. demonstrates strong financial performance and strategic growth, but faces challenges with cash flow management and high valuation. The bearish technical indicators and high P/E ratio suggest caution, despite positive earnings call insights.
Positive Factors
Market expansion
Illuccix received a positive decision on the MAA in Europe and country approvals in Denmark, Ireland, Luxembourg, Malta, the Netherlands, Norway, and Sweden as well as MAA approval in the UK and Brazil.
Product approvals
Approvals of Zircaix and Pixclara and Illuccix reimbursement decisions ex-US could lead to increased revenue.
Revenue growth
Telix reported Q1 total revenue of $186MM (AU$296MM, +31% Q/Q, +62% Y/Y), which could lead to an H1 beat as consensus currently estimates AU$547MM (vs the current H1 run-rate of AU$592).
Negative Factors
Operating costs
Higher-than-expected operating costs relative to consensus expectations.
Pricing impact
The rule requires reimbursement based on MUC pricing as opposed to a typical discount to WAC, which could result in a slight impact to Q3 and Q4 sales.
Transitional pass-through status
There is likely to be some impact on Illuccix revenue by the loss of transitional pass through status (TPT) on July 1.

Telix Pharmaceuticals (TLX) vs. iShares MSCI Australia ETF (EWA)

Telix Pharmaceuticals Business Overview & Revenue Model

Company DescriptionTelix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
How the Company Makes MoneyTelix Pharmaceuticals generates revenue through the commercialization of its diagnostic and therapeutic products in the field of oncology. The company earns money by selling its products directly to healthcare providers and institutions. Additionally, Telix may engage in strategic partnerships and collaborations with other pharmaceutical companies to co-develop or distribute its products, which can provide upfront payments, milestone payments, and royalty streams. The company's revenue model is also supported by licensing agreements for its proprietary technologies and intellectual property to other organizations, contributing further to its earnings.

Telix Pharmaceuticals Earnings Call Summary

Earnings Call Date:Aug 20, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Feb 19, 2026
Earnings Call Sentiment Positive
The earnings call presented a strong performance in terms of revenue growth, product expansion, and strategic acquisitions, highlighting the company's robust cash position and pipeline advancements. However, challenges such as SEC inquiries, gross margin pressure, and competitive pricing pressures were noted.
Q2-2025 Updates
Positive Updates
Record Revenue Growth
Telix reported a 63% year-on-year increase in group revenues for the first half of 2025, with revenues reaching $390 million.
Successful Product Expansion
The company has expanded its product line to include multiple approved products, with a significant rollout of Illuccix across Europe and upcoming launches of Zircaix and Pixclara.
Strong Precision Medicine Performance
Precision medicine revenues increased by 30% year-on-year, with EBITDA improving by 24% and gross margins steady at 64%.
Strategic Acquisitions and Infrastructure Growth
The company's global manufacturing and distribution sites have grown to 38, and its workforce has more than doubled, now exceeding 1,000 employees.
Robust Cash Position
Telix ended the first half of 2025 with $207 million in cash on hand and generated $18 million in operational cash flow.
Pipeline Progress
Significant progress was made in the therapeutics pipeline, including the launch of pivotal trials in prostate cancer and glioblastoma.
Negative Updates
SEC Information Request
Telix received a subpoena from the SEC regarding disclosure activity related to prostate cancer therapeutic candidates, although no allegations or charges have been made.
Gross Margin Pressure from RLS
The group's overall gross margin declined to 53% due to the addition of RLS third-party products and associated costs.
Pricing Challenges
The company faces competitive pricing pressures in the PSMA market, particularly following changes in reimbursement status.
Company Guidance
During the Telix Half Quarter 2025 Results and Investor Webcast, the company provided a detailed financial and operational performance overview for the first half of 2025. Telix reported a strong revenue growth of 63% year-on-year, with group revenues reaching $390 million, primarily driven by Illuccix and new third-party revenues from the RLS acquisition. The Precision Medicine business saw a revenue increase of 30% year-on-year, with EBITDA improving by 24%. Overall gross margin was reported at 53%, reflecting a mix of stable margins from Illuccix and contributions from RLS. The company made significant investments in global manufacturing infrastructure, increasing R&D spending by 47% compared to the previous year. Cash on hand was $207 million at the end of the half-year. Telix reaffirmed its full-year guidance, expecting revenues between $770 million and $800 million and an R&D investment increase of 20% to 25%. The company emphasized its strategic focus on long-term asset value and highlighted its progress in expanding its product offerings, geographic presence, and indications in the Precision Medicine and Therapeutics businesses.

Telix Pharmaceuticals Financial Statement Overview

Summary
Telix Pharmaceuticals Ltd. shows strong revenue and profit growth with improved margins and operational efficiency. The balance sheet is stable, though leverage levels should be monitored. Cash flow management needs improvement for sustainable operations.
Income Statement
85
Very Positive
Telix Pharmaceuticals Ltd. demonstrated strong revenue growth with a significant increase from $502.5M in 2023 to $783.2M in 2024, marking a 55.8% growth rate. The gross profit margin improved to 65.0%, showcasing efficient cost management. The net profit margin rose to 6.4%, reflecting enhanced profitability compared to previous years. The EBIT and EBITDA margins were healthy at 10.5% and 11.8%, respectively, indicating strong operational performance. Overall, the income statement reflects robust growth and improving profitability.
Balance Sheet
75
Positive
The company's financial position is solid with a debt-to-equity ratio of 1.02, suggesting a balanced approach to financing. The return on equity (ROE) improved to 8.8%, indicating better utilization of equity to generate profit. An equity ratio of 37.5% shows moderate reliance on equity financing. The balance sheet reflects a stable financial structure with steady equity growth, but there remains a slightly high leverage that could pose risks in volatile market conditions.
Cash Flow
65
Positive
Despite a lack of operating cash flow in the latest year, Telix Pharmaceuticals achieved a positive free cash flow of $9M, a decline from $13.1M in the previous year, indicating a need for better cash flow management. The absence of operating cash flow raises concerns regarding the sustainability of cash generation through operations. The free cash flow to net income ratio suggests limited conversion of profit into cash. Overall, cash flow management needs improvement to ensure long-term liquidity.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue783.21M502.55M160.10M7.60M5.21M
Gross Profit509.68M314.39M29.34M-29.77M-16.88M
EBITDA92.55M22.97M-92.84M-70.07M-44.94M
Net Income49.92M5.21M-104.08M-80.51M-44.89M
Balance Sheet
Total Assets1.52B398.30M260.59M109.81M164.44M
Cash, Cash Equivalents and Short-Term Investments710.35M123.24M116.33M22.04M77.94M
Total Debt581.45M17.45M10.45M2.54M2.21M
Total Liabilities948.22M249.39M178.44M106.17M84.44M
Stockholders Equity568.21M148.91M80.01M2.16M79.02M
Cash Flow
Free Cash Flow9.00M13.09M-77.83M-60.67M1.64M
Operating Cash Flow43.03M23.88M-63.97M-59.33M1.96M
Investing Cash Flow-135.17M-25.49M-17.00M-2.73M-1.09M
Financing Cash Flow638.92M10.19M174.96M2.85M34.12M

Telix Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Negative
Last Price18.40
Price Trends
50DMA
21.54
Negative
100DMA
23.82
Negative
200DMA
25.02
Negative
Market Momentum
MACD
-0.94
Negative
RSI
42.90
Neutral
STOCH
86.42
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TLX, the sentiment is Negative. The current price of 18.4 is above the 20-day moving average (MA) of 18.22, below the 50-day MA of 21.54, and below the 200-day MA of 25.02, indicating a neutral trend. The MACD of -0.94 indicates Negative momentum. The RSI at 42.90 is Neutral, neither overbought nor oversold. The STOCH value of 86.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:TLX.

Telix Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
$6.41B380.123.21%60.23%-66.98%
51
Neutral
$7.83B-0.18-40.10%2.29%21.46%-2.03%
$447.19M15.0819.93%0.34%
$2.04B-21.31%
$1.46B14.2754.79%
$238.43M-31.16%
56
Neutral
AU$44.73M-49.72%10.78%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:TLX
Telix Pharmaceuticals
18.40
-0.08
-0.43%
CLVLF
Clinuvel Pharmaceuticals
8.50
-1.93
-18.50%
MEOBF
Mesoblast Limited
1.54
0.88
133.33%
NURPF
Neuren Pharmaceuticals Limited
10.97
-0.03
-0.27%
PRRUF
Immutep Ltd
0.19
-0.06
-24.00%
AU:PTX
Prescient Therapeutics Limited
0.04
0.00
0.00%

Telix Pharmaceuticals Corporate Events

Telix Pharmaceuticals to Announce H1 2025 Financial Results
Jul 29, 2025

Telix Pharmaceuticals announced it will release its financial results for the first half of 2025 on August 21, 2025, followed by an investor webcast and conference call. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market position and investor confidence.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$31.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals to Release Shares from Voluntary Escrow
Jul 22, 2025

Telix Pharmaceuticals announced the release of 47,256 ordinary shares from voluntary escrow, which were initially issued to Lightpoint Medical Limited as part of the acquisition of its SENSEI® radio-guided surgery business. This release, scheduled for 31 July 2025, is in accordance with ASX Listing Rule 3.10A and may impact Telix’s market operations by increasing the liquidity of its shares, potentially affecting stakeholder interests.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$31.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals Achieves 63% Revenue Growth in Q2 2025
Jul 22, 2025

Telix Pharmaceuticals reported a significant 63% year-over-year increase in revenue for Q2 2025, reaching approximately $204 million. The company reaffirmed its FY 2025 revenue guidance of $770 million to $800 million. Key developments include the U.S. launch of Gozellix®, which has been assigned a Level II HCPCS code, and progress in the ProstACT™ Global Phase 3 trial with regulatory approvals for expansion into China, Japan, and Canada. These advancements highlight Telix’s strong market position and ongoing momentum in its therapeutic pipeline, despite competitive pricing pressures. The company’s strategic initiatives and regulatory achievements are expected to enhance its industry positioning and stakeholder value.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$31.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals’ Gozellix Secures Permanent HCPCS Code
Jul 9, 2025

Telix Pharmaceuticals announced that its next-generation PSMA PET imaging agent, Gozellix, has been granted a permanent HCPCS code by the U.S. Centers for Medicare & Medicaid Services, effective from October 1, 2025. This milestone supports provider billing and reimbursement, facilitating clinical adoption and expanded access to PSMA PET imaging for prostate cancer patients in the U.S., and marks an important step in Telix’s mission to improve access to precision medicine imaging.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals Announces Cessation of Securities
Jul 8, 2025

Telix Pharmaceuticals Limited announced the cessation of certain securities, specifically 67,000 share rights and 436,190 share appreciation rights, due to the lapse of conditional rights that were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s operational and financial strategies.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals Announces Quotation of New Securities on ASX
Jun 19, 2025

Telix Pharmaceuticals Limited has announced the quotation of 133,825 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code TLX. This move is part of the company’s strategy to enhance its capital structure and support its growth initiatives, potentially strengthening its market position and providing new opportunities for stakeholders.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals Updates Director’s Interest in Securities
Jun 17, 2025

Telix Pharmaceuticals has announced a change in the director’s interest, specifically for Dr. Christian Behrenbruch, who has acquired 166,483 Performance Share Appreciation Rights (PSARs) and 2,595 Deferred Share Rights (SRs) as part of his remuneration package. This change reflects the company’s commitment to aligning executive compensation with performance goals, potentially impacting the company’s operational focus and stakeholder interests by incentivizing leadership to achieve significant revenue milestones.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals Hosts Investor Day in New York City
Jun 11, 2025

Telix Pharmaceuticals Limited is hosting an Investor Day event in New York City, which will be a hybrid event allowing both in-person and virtual participation. This event is significant for stakeholders as it provides an opportunity for institutional investors and analysts to engage with the company, potentially impacting Telix’s market positioning and investor relations.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals Issues New Securities to Bolster Strategic Initiatives
Jun 4, 2025

Telix Pharmaceuticals has announced the issuance of 15,000 ordinary fully paid securities, effective May 30, 2025. This move reflects the company’s ongoing efforts to enhance its capital structure and support its strategic initiatives in the biotechnology sector, potentially impacting its market position and stakeholder interests.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals to Quote New Securities on ASX
Jun 4, 2025

Telix Pharmaceuticals Limited has announced the issuance of 139,741 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX) under the code TLX. This move is part of the company’s strategy to enhance its capital structure and support its ongoing operations, potentially strengthening its position in the biotechnology sector and providing value to its stakeholders.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals Issues New Equity Securities for Employee Incentives
Jun 4, 2025

Telix Pharmaceuticals Limited announced the issuance of new unquoted equity securities as part of an employee incentive scheme. The issuance includes Deferred Share Rights for both US and ex-US employees and Performance Share Appreciation Rights for US employees, reflecting the company’s strategy to incentivize and retain talent, potentially impacting its operational efficiency and market competitiveness.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$36.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals Issues New Share Appreciation Rights
Jun 4, 2025

Telix Pharmaceuticals Limited announced the issuance of 1,541,188 share appreciation rights as part of an employee incentive scheme. This move is part of the company’s strategy to incentivize and retain its workforce, potentially impacting its operational efficiency and market positioning positively.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals Announces Director Change
May 21, 2025

Telix Pharmaceuticals Limited announced the cessation of Harry Kevin McCann as a director effective May 21, 2025. McCann held indirect interests in the company through Monjoy Pty Limited and Cottesloe Pty Limited, with a total of 1,120,000 fully paid ordinary shares. This change in the board may impact the company’s governance structure and could have implications for its strategic direction.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals’ AGM Resolutions Successfully Passed
May 21, 2025

Telix Pharmaceuticals announced that all resolutions proposed at its Annual General Meeting were successfully passed by shareholders. This outcome reflects shareholder confidence and supports Telix’s strategic direction in the biopharmaceutical industry, potentially enhancing its market position and stakeholder value.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals Expands Global Reach with Product Approvals
May 21, 2025

Telix Pharmaceuticals announced the approval of its first-generation PSMA-PET imaging product, Illuccix®, and its osteomyelitis imaging agent, Scintimun®, in multiple countries. These approvals enhance Telix’s market presence and demonstrate its commitment to advancing medical imaging technologies. The company also highlighted its miniaturized surgical gamma probe, SENSEI®, which is registered for use in the U.S. and Europe, further solidifying its position in the medical imaging sector.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals Expands Global Product Approvals
May 21, 2025

Telix Pharmaceuticals Limited held its Annual General Meeting where the Chairman and CEO addressed shareholders. The company continues to expand its product approvals globally, with Illuccix® and Gozellix® receiving approvals from various international health agencies. This expansion strengthens Telix’s market position in the biopharmaceutical industry, potentially enhancing its operational capabilities and stakeholder value.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals to Release Shares from Voluntary Escrow
May 18, 2025

Telix Pharmaceuticals Limited announced the release of 684,437 ordinary shares from voluntary escrow, which were initially issued to ImaginAb Inc. as part of an asset acquisition. This release, scheduled for May 29, 2025, is in accordance with ASX Listing Rule 3.10A and may impact the company’s operations by increasing share liquidity. The move reflects Telix’s ongoing strategic efforts to enhance its market positioning and could have implications for stakeholders by potentially influencing share value and investor confidence.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.30 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals Expands Market Presence with New Securities Quotation
May 16, 2025

Telix Pharmaceuticals Limited has announced the quotation of 139,383 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective May 12, 2025. This move reflects the company’s ongoing efforts to enhance its market presence and provide value to its stakeholders by expanding its capital base.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.30 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals Issues New Equity Securities
May 16, 2025

Telix Pharmaceuticals Limited has announced the issuance of new ordinary fully paid securities, totaling 210,000 shares, on two separate dates in May 2025. This move is part of the company’s strategy to manage its equity and potentially strengthen its financial position, which may have implications for its market performance and stakeholder interests.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.30 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Telix Pharmaceuticals Announces Cessation of Share Rights
May 16, 2025

Telix Pharmaceuticals Limited has announced the cessation of 135,000 share rights under the ASX security code TLXAP, effective May 16, 2025. This announcement may impact the company’s capital structure and could have implications for its stakeholders, as it reflects changes in the company’s issued securities.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.30 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 22, 2025